Description: CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Home Page: www.cansinotech.com
401-420, Biomedical Park
Tianjin,
300457
China
Phone:
86 022 5821 3600
Officers
| Name | Title |
|---|---|
| Dr. Xuefeng Yu Ph.D. | Co-Founder, Executive Chairman, CEO & GM |
| Dr. Tao Zhu Ph.D. | Co-Founder, Deputy GM & Chief Scientific Officer |
| Dr. Dongxu Qiu MBA, Ph.D. | Co-Founder, Executive VP & Deputy GM |
| Dr. Shou-Bai Chao Ph.D. | COO, Deputy GM & Executive Director |
| Ms. Jing Wang | Chief Commercial Officer, Deputy GM & Executive Director |
| Mr. Chunlin Xin | Senior Director of New Technology Department |
| Mr. Yonghui Wu | Vice President of Marketing |
| Mr. Jin Cui | Board Secretary |
| Mr. Ming King Chiu FCIS, FCS | Joint Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4736 |
| Price-to-Sales TTM: | 2.037 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1494 |